Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Present at the 21st Annual Needham Growth Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 9, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the 21 st Annual Needham Growth Conference in New York City on  Tuesday, January 15, 2019  at  8:40
Toggle Summary Veracyte Announces Strategic Collaboration with Johnson & Johnson Innovation in Battle Against Lung Cancer
Alliance with the Lung Cancer Initiative at Johnson & Johnson to Accelerate Development of First Nasal Swab Test for Early Lung Cancer Detection Veracyte to Host Conference Call and Webcast on January 3, 2019 at 8:30 a.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan.


Date Event Details
Summary Toggle Jan 15, 2019 8:40 AM EST
21st Annual Needham Growth Conference
Summary Toggle Jan 10, 2019 11:30 PM PST
37th Annual J.P. Morgan Healthcare Conference

Please click here to access the live presentation at 11.30 a.m. PST

Please click here to access the live Q&A session at 12.00 p.m. PST


Title Documents

Corporate Presentation January 2019